- Home
- RNAZ
as 06-27-2025 4:00pm EST
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 6.1M | IPO Year: | 2021 |
| Target Price: | $280.00 | AVG Volume (30 days): | 32.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -469.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.15 - $970.20 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TransCode Therapeutics Inc. News
RNAZ Breaking Stock News: Dive into RNAZ Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
PR Newswire
2 months ago
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
PR Newswire
2 months ago
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
PR Newswire
2 months ago
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
NewMediaWire
2 months ago
IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
PR Newswire
2 months ago
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
Benzinga
2 months ago
EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug
PR Newswire
2 months ago
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Compare RNAZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAZ TransCode Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.